EVFM · Evofem Biosciences, Inc.

Evofem Biosciences, Inc. entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC. to commercialize SOLOSEC (secnidazole) 2 g oral granules in Sub-Saharan Africa. The agreement, effective April 24, 2026, has a five-year term. SOLOSEC is an FDA-approved single-dose oral treatment for bacterial vaginosis (BV) in females 12 years and older and trichomoniasis in people 12 years and older. Clovis Davis will lead distribution, promotion, marketing, and sales in the territory, with local regulatory filings based on Evofem's U.S. FDA registration dossier. This strategic partnership expands Evofem's commercial reach into a region with significant unmet need, as BV is estimated to affect 25% of women in Sub-Saharan Africa. The agreement includes exclusivity provisions, intellectual property protections, and confidentiality obligations. The press release also highlights Clovis Davis's parallel women's health initiatives in Ethiopia and Uganda using the OSOM BVBlue test. This transaction is material as it represents a new revenue-generating channel and geographic expansion for Evofem.